IMTX Stock Summary and Trading Ideas (Immatics N.V. - | NASDAQ:IMTX)

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Immatics N.V. - trades on the NASDAQ stock market under the symbol IMTX.

As of November 10, 2026, IMTX stock price declined to $6.42 with 1,156,692 million shares trading.

IMTX has a beta of 1.79, meaning it tends to be more sensitive to market movements. IMTX has a correlation of 0.24 to the broad based SPY ETF.

IMTX has a market cap of $977.28 million. This is considered a Small Cap stock.

Last quarter Immatics N.V. - reported $11 million in Revenue and -$.53 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.10.

In the last 3 years, IMTX traded as high as $13.77 and as low as $3.30.

The top ETF exchange traded funds that IMTX belongs to (by Net Assets): SPDW, SBIO, KOMP, CANC, ONEQ.

IMTX has underperformed the market in the last year with a price return of -29.1% while the SPY ETF gained +12.9%. IMTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.5% and -10.2%, respectively, while the SPY returned -2.8% and -2.0%, respectively.

IMTX support price is $6.14 and resistance is $6.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMTX shares will trade within this expected range on the day.